Canmab (Trastuzumab): Premium HER2+ Biosimilar Therapy – Global Supply by Ernest Oncology
In the cost-conscious yet quality-driven oncology landscape of 2026, Canmab (active ingredient Trastuzumab) has emerged as a vital biosimilar for the treatment of HER2-positive malignancies. As a recombinant DNA-derived monoclonal antibody, Canmab provides the same clinical efficacy and safety profile as the reference biologic, ensuring that life-saving targeted therapy remains accessible to global healthcare systems.
Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Canmab to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, providing end-to-end cold-chain solutions and rigorous documentation for seamless customs clearance.
Technical Product Profile: Canmab (Trastuzumab)
Canmab is a targeted biological therapy designed to interfere with the HER2 receptor, which is overexpressed in certain aggressive cancer types. It is typically supplied as a lyophilized powder for reconstitution and intravenous (IV) infusion.
Product Specifications
Active Ingredient: Trastuzumab (Biosimilar)
Available Strengths: 150 mg and 440 mg Vials
Pharmacological Class: Monoclonal Antibody / HER2 Receptor Antagonist
Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics.
Primary Clinical Indications
HER2+ Metastatic Breast Cancer (MBC): Used both as a monotherapy and in combination with taxanes.
Early Breast Cancer (EBC): Administered following surgery, chemotherapy, or radiotherapy to reduce the risk of recurrence.
Advanced Gastric Cancer: Specifically for HER2+ metastatic adenocarcinoma of the stomach or gastroesophageal junction.
Mechanism of Action: Precision Oncology
Canmab functions by targeting the extracellular domain of the Human Epidermal Growth Factor Receptor 2 (HER2).
Proliferation Inhibition: By binding to HER2, Canmab inhibits the signaling pathways that promote tumor cell growth.
Immune Recruitment: It triggers Antibody-Dependent Cellular Cytotoxicity (ADCC), prompting the patient's immune system to attack and destroy the cancer cells.
HER2 Shedding Prevention: It prevents the cleavage of the HER2 receptor, which can otherwise lead to more potent oncogenic signaling.
Global Export Excellence: UK, USA, UAE, Australia, & South Africa
Ernest Oncology specializes in navigating the strict regulatory and logistical requirements for shipping temperature-sensitive biosimilars from India to major international hubs.
United Kingdom & London: We supply NHS trusts and private oncology centers in London, ensuring all MHRA-compliant batch release and import paperwork is provided.
United States: Bulk supply for hospital networks and specialty wholesalers looking for cost-effective, high-quality Trastuzumab biosimilars from India.
Abu Dhabi & UAE: Supporting the advanced healthcare infrastructure of the Emirates with fast-track, secure, temperature-controlled shipping.
Australia: Strategic distribution to regional hospitals and wholesalers, strictly adhering to TGA biological import standards.
South Africa: Strengthening the African oncology sector by providing high-quality biosimilars that meet strict regulatory benchmarks.
📞 Contact Ernest Oncology — Pharmaceutical Exporter from India
(Group of Ernest Pharmaceutical Pvt. Ltd.)
Partner with a verified leader for the bulk procurement of oncology biologics and targeted biosimilars.
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 Instant Chat:
